JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 43 (final count)
- Started
- Aug 20, 2024
- Main results expected
- Sep 2, 2030
- Fully finished
- Sep 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Rate of Response with Curative Potential
Measured over: Up to 5 years
Progression Free Survival (PFS) Rate at 3-Year
Measured over: At 3-year
PFS Rate at 5-Year
Measured over: At 5-year
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06577025 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC